Research by a Michigan State University chemist could eventually lead to a quicker and easier way of developing protein-based drugs that are key to treating a number of diseases, including cancer, diabetes and hepatitis. Proteins used in drug manufacture and research often are made within genetically modified Escherichia coli, a one-cell bacteria. That protein tends to collect into what scientists call inclusion bodies. More at...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has formed an exclusive collaboration with the University of California, San Francisco (UCSF) to evaluate the potential of an RNAi therapeutic targeting a heterotrimeric G protein alpha-subunit, known as G-alpha q or GNAQ, for the treatment of metastatic uveal melanoma. More at...
Guided Therapeutics, Inc. (GT) (Pink Sheets: GTHP) today announced it submitted the first of three modules of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the LightTouchTM non-invasive cervical cancer detection device. More at...
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced that multiple studies of ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) will be presented at the 31st Annual San Antonio Breast Cancer Symposium on December 10-14, 2008. More at...
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment